login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CRISPR THERAPEUTICS AG (CRSP) Stock News
USA
- NASDAQ:CRSP -
CH0334081137
-
Common Stock
52.53
USD
+1.42 (+2.78%)
Last: 11/14/2025, 8:00:00 PM
52.57
USD
+0.04 (+0.08%)
After Hours:
11/14/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CRSP Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Zacks Investment Research
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
2 days ago - By: Zacks Investment Research
- Mentions:
REGN
BEAM
NTLA
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
4 days ago - By: The Motley Fool
- Mentions:
TSLA
COIN
ROKU
ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?
5 days ago - By: Benzinga
- Mentions:
ARWR
REGN
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial
5 days ago - By: Zacks Investment Research
- Mentions:
ALKS
VRTX
CRMD
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
6 days ago - By: Stocktwits
Retail Bulls Call CRISPR ‘Criminally Undervalued’ After Gene-Editing Breakthrough Cuts Cholesterol By 70%
6 days ago - By: Investor's Business Daily
- Mentions:
AAPL
NTLA
Why Gene-Editing Giants Crispr And Intellia Just Surged
6 days ago - By: Zacks Investment Research
- Mentions:
BRTX
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
6 days ago - By: CRISPR Therapeutics AG
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
8 days ago - By: CRISPR Therapeutics AG
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
8 days ago - By: Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note
9 days ago - By: Investor's Business Daily
- Mentions:
RY
RY.CA
NTLA
ALNY
...
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies
11 days ago - By: Zacks Investment Research
- Mentions:
VRTX
ANIP
NTLA
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
11 days ago - By: Benzinga
- Mentions:
ADPT
COIN
BEAM
ARKW
...
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys
12 days ago - By: Zacks Investment Research
- Mentions:
VRTX
ANIP
NTLA
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
12 days ago - By: The Motley Fool
- Mentions:
SMTC
SOUN
Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From Now
13 days ago - By: Zacks Investment Research
- Mentions:
ANIP
IMCR
RXRX
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
13 days ago - By: Zacks Investment Research
- Mentions:
VRTX
BEAM
NTLA
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
16 days ago - By: Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
18 days ago - By: Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know
18 days ago - By: Zacks Investment Research
- Mentions:
URGN
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
24 days ago - By: Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
a month ago - By: Zacks Investment Research
- Mentions:
REGN
BEAM
NTLA
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
a month ago - By: Zacks Investment Research
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
a month ago - By: Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
a month ago - By: CRISPR Therapeutics AG
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
2 months ago - By: CRISPR Therapeutics AG
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
Please enable JavaScript to continue using this application.